NCT02737072View on ClinicalTrials.gov

A Study of LY2510924 and Durvalumab in Participants With Solid Tumors

PHASE1TerminatedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

September 25, 2017

Study Completion Date

September 25, 2017

Conditions

Solid Tumor

Interventions

DRUG

LY2510924

Administered SQ

DRUG

Durvalumab

Administered IV

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY